CMTM1-v17 is a novel potential therapeutic target in breast cancer

Abstract

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing 1 (CMTM1) consists of at least 23 alternatively spliced isoforms designated CMTM1- v1-v23. In the present study, we detected CMTM1-v17 expression in multiple human normal and tumor tissues and found that CMTM1-v17 was highly expressed in testis and many tumor tissues including breast tumor. The overexpression of CMTM1-v17 in the breast cancer cell line MDA-MB-231 promoted cell proliferation and resistance to tumor necrosis factor-α (TNF-α)-induced apoptosis. Moreover, siRNA-mediated silencing of CMTM1-v17 sensitized MDA-MB-231 cells to TNF-α-induced apoptosis. We propose that CMTM1-v17 may be a novel potential target for therapy in breast cancer patients. The present study provides insight into a novel mechanism by which CMTM1-v17 enhances cellular proliferation and abrogates TNF-α-induced apoptosis. These findings also have implications for clinical practice as they highlight the potential for therapeutic targeting of CMTM1-v17 for the treatment of breast and other cancers in which CMTM1-v17 impacts cellular proliferation and survival.